World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
27976
World Ranking
12729
National Ranking
66

Overview

Markus Raderer is affiliated with the Medical University of Vienna in Austria and has a significant research footprint in the medical field, particularly in oncology. Their work spans several main fields, including Medicine with a focus on Oncology, Pathology and Forensic Medicine, Epidemiology, Pulmonary and Respiratory Medicine, and Neurology.

The primary research areas of Markus Raderer include lymphoma diagnosis and treatment, neuroendocrine tumor research advances, lung cancer research studies, neuroblastoma research and treatments, as well as COVID-19 and healthcare impacts. Additional topics of study include sarcoma diagnosis and treatment and COVID-19 clinical research studies.

The scientist's recent notable papers include:

  • Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2020, Annals of Oncology
  • Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509), 2021, Journal of Clinical Oncology
  • Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms, 2021, Endocrine Related Cancer
  • Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations, 2021, JAMA Oncology
  • CXCR4 PET imaging of mantle cell lymphoma using [68Ga]Pentixafor: comparison with [18F]FDG-PET, 2020, Theranostics

Frequent coauthors collaborating with Markus Raderer include:

  • Barbara Kiesewetter
  • Wolfgang Lamm
  • Matthias Preusser
  • Anna S. Berghoff
  • Philipp Melhorn

The scientist regularly publishes in several specialized medical journals. Some of the frequent publication venues include:

  • Annals of Oncology
  • Hematological Oncology
  • Therapeutic Advances in Medical Oncology
  • memo - Magazine of European Medical Oncology
  • ESMO Open

Best Publications

  • Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

    Martyn E. Caplin;Marianne Pavel;Jarosław B. Ćwikła;Alexandria T. Phan

  • Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    James C. Yao;Nicola Fazio;Simron Singh;Roberto Buzzoni

  • T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma.

    Berthold Streubel;Andrea Lamprecht;Judith Dierlamm;Lorenzo Cerroni

  • T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma.

    B Streubel;U Vinatzer;A Lamprecht;M Raderer

  • Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension

    Ventzislav Petkov;Wilhelm Mosgoeller;Rolf Ziesche;Markus Raderer

  • Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites.

    Streubel B;Simonitsch-Klupp I;Müllauer L;Lamprecht A

  • EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT

    A Ruskoné-Fourmestraux;W Fischbach;B M P Aleman;H Boot

  • Vasoactive Intestinal Peptide-Receptor Imaging for the Localization of Intestinal Adenocarcinomas and Endocrine Tumors

    I Virgolini;M Raderer;A Kurtaran;P Angelberger

  • Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma

    B Streubel;U Vinatzer;M Willheim;M Raderer

  • Inhibition of Metastases by Anticoagulants

    Michael Hejna;Markus Raderer;Christoph C. Zielinski

  • Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (IL-2), IL-4, and interferon-gamma in normal human T lymphocytes.

    Johannes Drach;Andrea Gsur;Gerhard Hamilton;Shourong Zhao

  • Clinical trials of agents that reverse multidrug resistance. A literature review.

    Markus Raderer;Werner Scheithauer

  • Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.

    Alexander Becherer;Monica Szabó;Georgios Karanikas;Patrick Wunderbaldinger

  • Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study

    Martyn E Caplin;Marianne Pavel;Jarosław B Ćwikła;Alexandria T Phan

  • Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

    W. Scheithauer;B. Schüll;H. Ulrich-Pur;K. Schmid

  • Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT lymphoma)

    Markus Raderer;Barbara Kiesewetter;Andrés J. M. Ferreri

  • Primary Follicular Lymphoma of the Duodenum Is a Distinct Mucosal/Submucosal Variant of Follicular Lymphoma: A Retrospective Study of 63 Cases

    Ana-Iris Schmatz;Berthold Streubel;Elisabeth Kretschmer-Chott;Andreas Püspök

  • Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality

    Noemi Pavo;Markus Raderer;Martin Hülsmann;Stephanie Neuhold

  • Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    E. Zucca;M. Dreyling

  • Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Commentary

    M. J. S. Dyer;R. Siebert;B. Streubel;U. Vinatzer

Frequent Co-Authors

Andreas Chott
Andreas Chott Medical University of Vienna
Christoph C. Zielinski
Christoph C. Zielinski Medical University of Vienna
Werner Scheithauer
Werner Scheithauer Medical University of Vienna
Guido Rindi
Guido Rindi Catholic University of the Sacred Heart
Ulrich Jäger
Ulrich Jäger Medical University of Vienna
Bruno Niederle
Bruno Niederle Medical University of Vienna
Juan W. Valle
Juan W. Valle University of Manchester
Philippe Ruszniewski
Philippe Ruszniewski Université Paris Cité
Matthias Preusser
Matthias Preusser Medical University of Vienna
Matthew H. Kulke
Matthew H. Kulke Boston Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring options related to studying Medicine in the USA, there are many online degrees and accelerated career pathways to consider. For nurses aiming to advance their careers quickly, programs like the shortest online dnp program and the shortest dnp program are designed for efficiency while maintaining educational quality.

Those just beginning their healthcare careers may benefit from an accelerated lpn program, which allows you to quickly qualify as a Licensed Practical Nurse and enter the medical workforce. For those interested in mental health care, the shortest pmhnp program is a fast-track way to become a Psychiatric Mental Health Nurse Practitioner.

These online options provide flexible schedules and quicker paths to advanced roles in healthcare. However, it's important to weigh factors like accreditation, program intensity, and long-term career goals before enrolling.

Best Scientists Citing Markus Raderer

Trending Scientists